Chemotherapy provided significant benefit in stage III/IV patients (aHR = 0.67, 95% CI 0.49–0.93, p = 0.02), those aged ≥59 years (aHR = 0.61, 95% CI 0.40–0.93, p = 0.02), males (aHR = 0.57, 95% CI 0.39–0.82, p < 0.01), patients with lymphatic metastasis (aHR = 0.40, 95% CI 0.26–0.63, p < 0.01), and patients with normal CEA or NSE levels (both p < 0.05) (Figure 6B). Here, ENO2 is linked to Lymphatic Metastasis.